Evommune (EVMN) vs Fulcrum Therapeutics (FULC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Evommune (EVMN) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 62.4% versus a loss of 67.3%. Evommune is the larger company by market cap ($291.1 million vs $281.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | FULC |
|---|---|---|
| Share price | $7.04 | $3.69 |
| Market cap | $291.10M | $281.85M |
| 1-day change | -2.76% | -0.54% |
| YTD return | -58.88% | -67.37% |
| 1-year return | -62.37% | -67.32% |
| 5-year return | — | -75.50% |
| EPS (TTM) | $-3.83 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.00M | $0 |
| Revenue growth (YoY) | +85.71% | -100.00% |
| Net income (latest FY) | $-68.87M | $-74.88M |
| Operating margin | -623.62% | — |
| Net margin | -529.77% | — |
| 52-week high | $33.20 | $15.74 |
| 52-week low | $4.94 | $2.83 |
| Distance from 52-week high | -78.80% | -76.56% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +210.94% | -0.54% |
| Average volume | 841.65K | 1.37M |
| Shares outstanding | 41.35M | 76.38M |
| Employees | 48 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Evommune grew revenue faster in its latest fiscal year (+85.71% vs -100.00%).
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
EVMN vs FULC FAQ
Which is bigger, Evommune or Fulcrum Therapeutics?
Evommune (EVMN) is larger, with a market capitalization of $291.10M compared with $281.85M for Fulcrum Therapeutics (FULC).
Which stock has performed better over the past year, EVMN or FULC?
EVMN returned -62.37% over the past 12 months, compared with -67.32% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Evommune and Fulcrum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.